Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
EjrkfBG9jnp5Phgn
